Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

PPD completes Evidera acquisition
November 2016
SHARING OPTIONS:

WILMINGTON, N.C.—Global clinical research organization Pharmaceutical Product Development LLC (PPD) recently completed its acquisition of Evidera, a provider of evidence-based solutions to demonstrate the real-world effectiveness and value of biopharmaceutical products. Operating as a wholly owned subsidiary of PPD, Evidera will continue to be led by its current management team, and Evalytica will continue to operate as a wholly owned subsidiary of Evidera.
 
“By leveraging Evidera’s scientific research and consulting capabilities and PPD’s operational excellence in global clinical research, our clients can greatly enhance their ability to navigate today’s complex and fast-evolving R&D and reimbursement landscape,” said David Simmons, chairman and CEO of PPD. “For biopharma companies, our considerable joint expertise will benefit clients in executing comprehensive development strategies for regulatory success, while in parallel collecting the necessary evidence to support discussions with payers and health authorities on pricing and reimbursement. These combined strengths will further support clients in bringing innovative therapies to patients in need.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.